BCL2L11 and B-cell chronic lymphocytic leukemia: Combining the AXL inhibitor TP-0903 with Bruton's tyrosine kinase inhibitors (e.g., ibrutinib) reduced the expression of Mcl-1, Bcl-2 and XIAP, while upregulated Bim expression, resulting in increased B-CLL apoptosis [630].